Key result
Antiplatelet non-persistence reaches ~33% at five years among older patients with newly diagnosed PAD.
Why the study?
Antiplatelet therapy requires lifelong administration in PAD, but non-persistence patterns and associated patient- and medication-related characteristics in older patients required analysis.
Cohort (n=9,178)
One-third of older patients with newly diagnosed peripheral arterial disease become non-persistent with antiplatelet therapy within 5 years, highlighting the need for targeted adherence interventions.
Answers are grounded in this paper and cite their sources.
Non-persistence with antiplatelet therapy in PAD may support adherence interventions; leaves open their impact on outcomes without prospective trials.
Introduction: Antiplatelet therapy needs to be administered life-long in patients with peripheral arterial disease (PAD). Our study was aimed at 1) the analysis of non-persistence with antiplatelet medication in older PAD patients and 2) identification of patient- and medication-related characteristics associated with non-persistence. Methods: The study data was retrieved from the database of the General Health Insurance Company. The study cohort of 9,178 patients aged ≥ 65 years and treated with antiplatelet medications was selected from 21,433 patients in whom PAD was newly diagnosed between 01/2012 and 12/2012. Patients with a 6 months treatment gap without antiplatelet medication prescription were classified as non-persistent. Characteristics associated with non-persistence were identified using the Cox regression. Results: At the end of the 5 years follow-up, 3,032 (33.0%) patients were non-persistent. Age, history of ischemic stroke or myocardial infarction, clopidogrel or combination of aspirin with clopidogrel used at the index date, higher co-payment, general practitioner as index prescriber and higher overall number of medications were associated with persistence, whereas female sex, atrial fibrillation, anxiety disorders, bronchial asthma/chronic obstructive pulmonary disease, being a new antiplatelet medication user (therapy initiated in association with PAD diagnosis), and use of anticoagulants or antiarrhythmic agents were associated with non-persistence. Conclusion: In patients with an increased probability of non-persistence, an increased attention should be paid to improvement of persistence.
No takes yet. Share an insight, caveat, or question.
Wawruch et al. (2021) conducted a cohort in Peripheral Arterial Disease (n=9,178). Antiplatelet medications was evaluated on Non-persistence with antiplatelet medication (defined as a 6-month treatment gap). At the end of a 5-year follow-up, 33.0% of older patients newly diagnosed with peripheral arterial disease were non-persistent with their prescribed antiplatelet medications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: